重组人血管内皮抑素联合体部伽玛刀治疗原发性肝癌的临床观察

目的观察重组人血管内皮抑素（恩度）联合体部伽玛刀治疗原发性肝癌的疗效和不良反应。方法：回顾性分析我院2009年01月-2014年12月收治的60例原发性肝癌，按治疗方式的不同分成两组，A组：恩度联合体部伽玛刀组；B组：单纯行体部伽玛刀组。结果：联合治疗组的近期疗效有效率为66．7％，单纯放疗组为43．3％，联合治疗组与单纯放疗组比较，差异有统计学意义（p〈0．05）。且联合治疗组生活质量、AFP水平均显著改善（p〈0．05），不良反应发生率差异无统计学意义（p〉0．05）。结论：恩度与体部伽玛刀联合治疗原发性肝癌疗效较好，生活质量明显改善，不良反应能耐受，值得临床进一步推广应用。

Objective To obeserve the efficacy and safety of recombinant human vascular endothelial endostatin commonwealth of Gamma Knife treatment of liver cancer. Methods： We performed a retrospective analysis of 60 cases of primary liver cancer in our hospital from January 2009 to December 2014, and they were divided into two groups according to the different treatments, A group： endostar Commonwealth Gamma Knife; group B： simple line body gamma knife group. Results： Compared with r-knife group, the overall objective response rate in combination group was 66.7% versus 43.3% in Gamma Knife group,which was significantly different （p〈0.05）, as well as the quality of life and decreased level of AFP. The side effects were mild and tolerable in both groups without significantly difference （p〉0.05）. Conclusion： Endostar combined body gamma knife is safe and effective in the treatment of liver cancer, which should be further explored in clinic.